Soltamox

Sexual Precocity, Gynecomastia, Ovulation induction therapy + 12 more
Treatment
12 FDA approvals
20 Active Studies for Soltamox

What is Soltamox

TamoxifenThe Generic name of this drug
Treatment SummaryTamoxifen is a type of medication used to treat certain types of breast cancer and to prevent the development of breast cancer in high risk individuals. It is usually given alone or in combination with other treatments. Tamoxifen has generally been replaced by another drug called anastrozole, which has been found to have better survival rates, fewer side effects, and better patient compliance. Tamoxifen was approved by the FDA in 1977.
Nolvadexis the brand name
image of different drug pills on a surface
Soltamox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nolvadex
Tamoxifen
1990
60

Approved as Treatment by the FDA

Tamoxifen, also called Nolvadex, is approved by the FDA for 12 uses which include Invasive Breast Cancer and Malignant Neoplasms .
Invasive Breast Cancer
Malignant Neoplasms
Estrogen Receptors
Breast Cancer
Ductal Carcinoma In Situ
Malignant Neoplasms
Breast Cancer
Breast
Breast Surgery
Carcinoma, Intraductal, Noninfiltrating
Breast Cancer Radiation
High Risk

Effectiveness

How Soltamox Affects PatientsTamoxifen is a drug that can help stop the growth and spread of certain types of cancer. Its effects last for about two weeks, so it needs to be taken regularly for it to be effective. Taking too much of it can lead to breathing difficulties or seizures, so it is important to take the correct dose. It can also increase the risk of developing cancer of the uterus.
How Soltamox works in the bodyTamoxifen blocks the effects of estrogen on cells, which helps stop the growth of tumors. It does this by decreasing tumor growth factors, increasing a hormone that binds to estrogen, and causing apoptosis (cell death) in estrogen-sensitive cells. This cell death is thought to be caused by an increase in calcium ion levels or the introduction of a tumor growth factor.

When to interrupt dosage

The suggested dose of Soltamox relies upon the diagnosed condition, including Ovulation induction therapy, Malignant Neoplasms and McCune Albright Syndrome. The amount of dosage is contingent upon the method of delivery featured in the table below.
Condition
Dosage
Administration
Ovulation induction therapy
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Breast Surgery
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
High Risk
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Fibromatosis, Aggressive
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Estrogen Receptors
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Breast Cancer Radiation
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Breast
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Sexual Precocity
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Breast Cancer
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Carcinoma, Intraductal, Noninfiltrating
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Gynecomastia
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Ovarian Cancer
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Fibrous Dysplasia, Polyostotic
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Malignant Neoplasms
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit
Malignant Neoplasms
, 10.0 mg, 10.0 mg/mL, 20.0 mg, 2.0 mg/mL, 1.0 mg/mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Kit

Warnings

Soltamox has four contraindications, so its usage should be avoided when going through any of the conditions shown in the subsequent table.Soltamox Contraindications
Condition
Risk Level
Notes
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
Pulmonary Embolism
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Tamoxifen may interact with Pulse Frequency
There are 20 known major drug interactions with Soltamox.
Common Soltamox Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Tamoxifen.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Tamoxifen.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Tamoxifen.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Tamoxifen.
Anastrozole
Major
The serum concentration of Anastrozole can be decreased when it is combined with Tamoxifen.
Soltamox Toxicity & Overdose RiskTaking too much tamoxifen can cause difficulty breathing and seizures in animals, and dizziness, tremors, and difficulty with coordination in humans. If someone overdoses on tamoxifen, supportive care should be provided as there is no specific treatment for an overdose.
image of a doctor in a lab doing drug, clinical research

Soltamox Novel Uses: Which Conditions Have a Clinical Trial Featuring Soltamox?

Presently, there are 930 active trials examining the potential of Soltamox to mitigate Breast Cancer Radiation, Gynecomastia and Malignant Neoplasms.
Condition
Clinical Trials
Trial Phases
Breast Cancer Radiation
1 Actively Recruiting
Phase 2
Malignant Neoplasms
0 Actively Recruiting
Fibrous Dysplasia, Polyostotic
1 Actively Recruiting
Phase 2
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Ovulation induction therapy
0 Actively Recruiting
Breast Surgery
0 Actively Recruiting
Estrogen Receptors
0 Actively Recruiting
Malignant Neoplasms
5 Actively Recruiting
Phase 2, Not Applicable
Breast
0 Actively Recruiting
Carcinoma, Intraductal, Noninfiltrating
0 Actively Recruiting
Sexual Precocity
0 Actively Recruiting
Gynecomastia
0 Actively Recruiting
Fibromatosis, Aggressive
2 Actively Recruiting
Phase 2, Phase 3
Ovarian Cancer
13 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3
High Risk
0 Actively Recruiting

Soltamox Reviews: What are patients saying about Soltamox?

5Patient Review
2/14/2013
Soltamox for Breast Cancer
4.7Patient Review
9/15/2012
Soltamox for Breast Cancer

Patient Q&A Section about soltamox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is SOLTAMOX used for?

"SOLTAMOX can be used to treat adults with estrogen receptor-positive breast cancer that has spread to other parts of the body or early stage breast cancer after surgery and radiation."

Answered by AI

Who makes SOLTAMOX?

"Savient's wholly-owned subsidiary Rosemont Pharmaceuticals Ltd. located in Leeds, U.K. has created Soltamox. This is the first oral liquid product entry into the market from Savient's wholly-owned U.K. subsidiary. The product is an oral solution of tamoxifen, which will be available in the United States."

Answered by AI

How do you take SOLTAMOX?

"Doses of SOLTAMOX greater than 20 mg per day should be given in divided doses (morning and evening), as greater doses yield no additional clinical benefit in the adjuvant setting for breast cancer."

Answered by AI

How much does SOLTAMOX cost?

"The price of Soltamox is around $1,354.63, cheaper than the average retail price of $1,552.16 by 12%."

Answered by AI

Clinical Trials for Soltamox

Image of BAMF Health in Grand Rapids, United States.

GEH300079 PET/CT for Colorectal Cancer

18+
All Sexes
Grand Rapids, MI
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study. The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.
Phase 2 & 3
Waitlist Available
BAMF HealthGE Healthcare
Image of Univeristy of North Carolina at Chapel Hill in Chapel Hill, United States.

Educational Videos for Gynecologic Cancer

18+
Female
Chapel Hill, NC
This pilot study aims to estimate rates of genetic testing in patients with ovarian and endometrial cancer before and after the implementation of educational videos about genetic testing. Subjects will be asked to view one of three videos relevant to their cancer diagnosis and genetic testing, and have the option to complete a brief satisfaction survey. A chart review to evaluate rates of genetic testing ordered and referrals placed to Genetics before and after the implementation of the videos will be conducted. Up to 15-20% of ovarian cancer and 3-5% of endometrial cancer is due to inherited genetic mutation. Given this association, the National Comprehensive Cancer Network (NCCN) recommends genetic counseling and testing for all individuals with a diagnosis of ovarian cancer and endometrial cancer. Some challenges to obtaining genetic counseling and testing include missed identification and referral of eligible patients by providers, lack of provider knowledge, and busy clinic visits limiting time for informed consent and maintaining patient autonomy for genetic testing. Although heterogeneous, the literature supports multimedia use in cancer genetics. However, there is a paucity of data in the field of gynecologic oncology for the role of integrating a multimedia approach to genetic counseling.
Recruiting
Has No Placebo
Univeristy of North Carolina at Chapel HillKatherine Tucker, MD
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Algorithm-Based Treatment Options for Advanced Breast Cancer

18 - 120
All Sexes
Bethesda, MD
Background: Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat. Researchers want to know if an algorithm (ENLIGHT) can help choose approved drugs that will treat these cancers more effectively. Objective: To test whether ENLIGHT can find better treatments for aggressive breast cancers. Eligibility: People aged 18 years and older with triple-negative or endocrine therapy resistant breast cancer; the cancer must have either failed to respond to treatment or come back after treatment. Design: Participants will be screened. A sample of tissue taken from the tumor will be tested using ENLIGHT as well as another method (TruSight Oncology 500). Participants will be assigned to 1 of 3 groups based on the algorithm search results: Group 1: No drug option was recommended. Participants will continue with their standard treatment with their local doctors. Group 2: A drug already approved for the participant's disease was recommended, but the participant has not yet received it. These results will be sent to the participant's local doctors. Participants may return to the NIH if their disease gets worse after using the suggested drugs. Group 3: A drug approved for other uses was recommended. Participants will be treated with the recommended drugs at the NIH; their care will be managed by an NIH doctor. They will continue to receive treatment as long as the drugs are helping them. They will have follow-up visits for 2 years after treatment ends. Participants who are not treated at the NIH will be contacted for a check on their health every 3 months for 2 years.
Waitlist Available
Has No Placebo
National Institutes of Health Clinical CenterPadma S Rajagopal, M.D.
Have you considered Soltamox clinical trials? We made a collection of clinical trials featuring Soltamox, we think they might fit your search criteria.Go to Trials
Image of University of Calgary in Calgary, Canada.

Exercise Programs for Cancer

18+
All Sexes
Calgary, Canada
EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-trained exercise specialists in Canada, outside of the research setting. Considering the negative impact cancer and its treatments have on fitness and physical activity levels, community-based efforts towards improving access, uptake and maintenance of exercise programming are needed. This study will evaluate the benefits of a community-based or online EXCEL exercise program for people living with and beyond cancer across Canada, using a streamlined intake process compared to the original EXCEL Study (HREBA.CC-20-0098, NCT04478851). This 8 to 12-week program (intervention) will be delivered in-person or over virtual platform. It includes twice weekly supervised exercise classes.
Recruiting
Has No Placebo
University of Calgary (+4 Sites)Nicole Culos-Reed, PhD
Have you considered Soltamox clinical trials? We made a collection of clinical trials featuring Soltamox, we think they might fit your search criteria.Go to Trials
Image of University of Arkansas for Medical Sciences in Little Rock, United States.

Mind-Body Intervention for Sexual Dysfunction in Breast Cancer Survivors

18 - 50
Female
Little Rock, AR
The goal of this clinical trial is to test the efficacy of a nurse-led psychoeducational sexual health intervention for young women breast cancer survivors. The main questions it aims to answer are: 1. What is the feasibility of this intervention in an online, private setting? 2. What is the effect of this intervention on reducing menopausal symptoms, improving sexual functioning, and enhancing body image? Participants will participate in a nurse-led psychoeducational intervention for 8 sessions lasting approximately an hour each over the course of 16 weeks. Each participant will complete survey items at the beginning, end, and six-weeks after the last session. Participants will be compensated up to $150 in gift cards as a thank-you for their time.
Waitlist Available
Has No Placebo
University of Arkansas for Medical SciencesPearman D Parker, PhD, MPH, RN
Have you considered Soltamox clinical trials? We made a collection of clinical trials featuring Soltamox, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security